Ramipril reduced the rate of new-onset heart failure from 11.5% to 9.0% (RR 0.77; 95% CI 0.68-0.87; P<0.0001) in high-risk patients without known low ejection fraction or heart failure.
RCT (n=9,297)
Double-blind
randomly assigned
Effect estimate: RR 0.77 (95% CI 0.68 to 0.87)
Absolute Event Rate: 9% vs 11.5%
p-value: p=<0.0001
BACKGROUND: Previous trials in the prevention of heart failure have been restricted to patients with low ejection fraction or hypertension. We assessed an angiotensin-converting enzyme (ACE) inhibitor, ramipril, to prevent the development of heart failure in high-risk patients without known low ejection fraction or heart failure. METHODS AND RESULTS: We randomly assigned 9297 patients to receive double-blind ramipril (10 mg daily) or matching placebo for 4.5 years. Death attributable to heart failure, hospitalization for heart failure, initiation of open-label ACE inhibitor for heart failure, or development of typical signs or symptoms of heart failure developed in 951 patients and was associated with a 4.01-fold increase in the risk of death (P<0.0001). The rate of developing heart failure was significantly increased with coronary disease (risk ratio, 2.17), microalbuminuria (1.82), left ventricular hypertrophy (1.47), increasing age (by decade, 1.37), and diabetes (1.36). Ramipril reduced new-onset heart failure rate from 11.5% to 9.0% (relative risk, 0.77; 95% CI, 0.68 to 0.87; P<0.0001). Ramipril consistently reduced heart failure rate both in those with (relative risk, 0.87) and those without an interim myocardial infarction (relative risk, 0.78). Ramipril also reduced the heart failure rate more in patients with baseline systolic pressure above the median (139 mm Hg) (relative risk, 0.67) compared with those below the median (relative risk, 0.91; P=0.024 for interaction of group by treatment). CONCLUSION: Ramipril significantly reduces the rate of development of heart failure in patients at high risk of cardiovascular events.
Arnold et al. (Mon,) conducted a rct in High cardiovascular risk without known low ejection fraction or heart failure (n=9,297). Ramipril vs. Placebo was evaluated on Death attributable to heart failure, hospitalization for heart failure, initiation of open-label ACE inhibitor for heart failure, or development of typical signs or symptoms of heart failure (RR 0.77, 95% CI 0.68 to 0.87, p=<0.0001). Ramipril reduced the rate of new-onset heart failure from 11.5% to 9.0% (RR 0.77; 95% CI 0.68-0.87; P<0.0001) in high-risk patients without known low ejection fraction or heart failure.